+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast to 2030- Product Image
Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast to 2030- Product Image
Sale

Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674772
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Immuno-oncology Clinical Trials Market is undergoing a rapid transformation as industry players seek innovation, operational agility, and regionally tailored strategies in a complex regulatory and scientific environment. Senior leaders are facing high-impact decisions to optimize trial design, supply chain resilience, and portfolio prioritization amid geopolitical shifts and intensified competition.

Market Snapshot: Immuno-oncology Clinical Trials Market

The Immuno-oncology Clinical Trials Market grew from USD 6.58 billion in 2024 to USD 7.40 billion in 2025. It is expected to continue growing at a CAGR of 11.84%, reaching USD 12.89 billion by 2030. This sustained momentum reflects a robust clinical development pipeline, with escalating interest in next-generation therapies and combination regimens. The market’s expansion is attributed to increasing investment in biomarker-driven trial designs, a diverse range of sponsor profiles, and accelerating demand for therapies that leverage the body’s immune system for durable cancer responses.

Scope & Segmentation

This report delivers comprehensive, multi-level segmentation of the market to inform strategic decisions:

  • Therapy Type: Adoptive Cell Therapies (CAR-T, NK Cell Therapy, TCR-T), Cancer Vaccines (Dendritic Cell, DNA, Peptide), Checkpoint Inhibitors (CTLA-4, PD-1, PD-L1), Cytokine Therapies (Interferon Alpha, Interferon Gamma, Interleukin-2), Oncolytic Viruses.
  • Trial Phase: Phase I, Phase II, Phase III, Phase IV.
  • Indication: Hematological Malignancies (Leukemia, Lymphoma, Myeloma), Solid Tumors (Breast, Colorectal, Lung, Melanoma).
  • Sponsor Type: Academic Institutions, Biotechnology Companies, Consortiums, Pharmaceutical Companies.
  • Trial Type: Interventional, Observational.
  • Patient Enrollment: Large Scale, Medium Scale, Small Scale.
  • Geographies: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, and key regional markets), Asia-Pacific (China, India, Japan, Australia, South Korea, Southeast Asia and others).
  • Key Companies: Bristol-Myers Squibb Company, Merck & Co., Roche Holding AG, AstraZeneca PLC, Novartis AG, Pfizer Inc., Johnson & Johnson, Amgen Inc., Sanofi S.A., GlaxoSmithKline plc.

Key Takeaways for Strategic Leadership

  • Immuno-oncology is a rapidly evolving field, with checkpoint inhibitors and adoptive cell therapies at the forefront of innovation, requiring flexible clinical operations and early integration of emerging biomarkers.
  • Regulatory agencies are adopting new approval pathways and digital tools, increasing opportunities for adaptive trial designs and real-time data review, which speed development but demand rigorous operational coordination.
  • Patient-centric approaches such as decentralized and home-based monitoring are now mainstream, improving trial retention and enhancing real-world evidence but necessitating investment in remote technologies.
  • Sponsor strategies vary, with biotech firms driving early-stage innovation and large pharmaceutical companies leveraging global networks for late-phase and registration trials via partnerships and licensing models.
  • Segmenting trials by indication, sponsor type, and enrollment size helps organizations tailor resource allocation and mitigate risks, especially for rare or complex conditions requiring specialized endpoints.
  • Regional market dynamics significantly influence trial logistics and implementation; Asia-Pacific is showing the strongest growth in government-sponsored innovation and streamlined regulatory environments.

Tariff Impact: Adjusting Trial Supply Chains

Recent United States tariff policy shifts have imposed new duties on clinical trial materials, increasing operational costs for sponsors reliant on international supply chains. Companies are responding by relocating key manufacturing to domestic or tariff-exempt jurisdictions and establishing partnerships with local contract manufacturers. This strategy helps reduce cross-border supply volatility but introduces new challenges in scaling and maintaining quality standards. Diversification of sourcing and proactive logistics planning are essential to navigate these changes while ensuring uninterrupted trial progress.

Methodology & Data Sources

This analysis is grounded in extensive secondary research across industry publications, regulatory reports, and global trial registry databases. Key quantitative insights were validated through expert interviews with clinical investigators, regulatory professionals, and corporate executives. Triangulation of qualitative and quantitative findings ensured segmentation accuracy and trend reliability. Peer review and methodological audits maintained rigor and data integrity throughout the research process.

Why This Report Matters

  • Strategic guidance for executives navigating evolving immuno-oncology trial designs, emerging technologies, and changing regulatory standards.
  • Detailed segmentation enables precise benchmarking against competitors and identification of new market opportunities.
  • Insight into building resilient supply chains and adopting patient-centric trial models in a shifting global landscape.

Conclusion

The Immuno-oncology Clinical Trials Market is defined by fast-paced scientific advances, evolving operational models, and region-specific regulatory imperatives. This report equips decision-makers with the intelligence needed to optimize trial execution, respond to market disruptions, and sustain a leadership position as the sector continues to transform.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immuno-oncology Clinical Trials Market, by Therapy Type
8.1. Introduction
8.2. Adoptive Cell Therapies
8.2.1. Car-T
8.2.2. Nk Cell Therapy
8.2.3. Tcr-T
8.3. Cancer Vaccines
8.3.1. Dendritic Cell Vaccines
8.3.2. Dna Vaccines
8.3.3. Peptide Vaccines
8.4. Checkpoint Inhibitors
8.4.1. Ctla-4 Inhibitors
8.4.2. Pd-1 Inhibitors
8.4.3. Pd-L1 Inhibitors
8.5. Cytokine Therapies
8.5.1. Interferon Therapies
8.5.1.1. Interferon Alpha
8.5.1.2. Interferon Gamma
8.5.2. Interleukin-2
8.6. Oncolytic Viruses
9. Immuno-oncology Clinical Trials Market, by Trial Phase
9.1. Introduction
9.2. Phase I
9.3. Phase Ii
9.4. Phase Iii
9.5. Phase Iv
10. Immuno-oncology Clinical Trials Market, by Indication
10.1. Introduction
10.2. Hematological Malignancies
10.2.1. Leukemia
10.2.2. Lymphoma
10.2.3. Myeloma
10.3. Solid Tumors
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Lung Cancer
10.3.4. Melanoma
11. Immuno-oncology Clinical Trials Market, by Sponsor Type
11.1. Introduction
11.2. Academic Institutions
11.3. Biotechnology Companies
11.4. Consortiums
11.5. Pharmaceutical Companies
12. Immuno-oncology Clinical Trials Market, by Trial Type
12.1. Introduction
12.2. Interventional
12.3. Observational
13. Immuno-oncology Clinical Trials Market, by Patient Enrollment
13.1. Introduction
13.2. Large Scale
13.3. Medium Scale
13.4. Small Scale
14. Americas Immuno-oncology Clinical Trials Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Immuno-oncology Clinical Trials Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Immuno-oncology Clinical Trials Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bristol-Myers Squibb Company
17.3.2. Merck & Co., Inc.
17.3.3. Roche Holding AG
17.3.4. AstraZeneca PLC
17.3.5. Novartis AG
17.3.6. Pfizer Inc.
17.3.7. Johnson & Johnson
17.3.8. Amgen Inc.
17.3.9. Sanofi S.A.
17.3.10. GlaxoSmithKline plc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET MULTI-CURRENCY
FIGURE 2. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2024 VS 2030 (%)
FIGURE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 88. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 89. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 90. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 92. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 94. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 96. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 97. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 98. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 99. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 100. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 101. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 103. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 105. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 106. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 109. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 166. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 167. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 168. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 169. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 171. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 172. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 173. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 175. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 178. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 179. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 181. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 182. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 185. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 186. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 188. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 189. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 190. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 191. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 205. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 206. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 207. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 208. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 210. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 211. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 212. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 214. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 215. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 216. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 217. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 218. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 219. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 221. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 223. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 224. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 225. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 227. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 228. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 229. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 230. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 270. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 271. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 272. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 273. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 275. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 276. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 277. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 278. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 279. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 280. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 281. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2030 (USD MILLION)
TABLE 282. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS IMMUNO-ONCOLOGY CLINI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immuno-oncology Clinical Trials market report include:
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Roche Holding AG
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.89 Billion
Compound Annual Growth Rate11.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immuno-Oncology Market by Therapy Type, Indication, End User, Line of Therapy, Mechanism - Global Forecast to 2030 - Product Image

Immuno-Oncology Market by Therapy Type, Indication, End User, Line of Therapy, Mechanism - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Immuno Oncology Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Immuno Oncology Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From

About the Immuno Oncology Clinical Trials Market

Immuno Oncology (IO) is a rapidly growing field of oncology drug development that focuses on harnessing the body's own immune system to fight cancer. IO drugs are designed to target and block specific pathways that cancer cells use to evade the immune system. These drugs can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. IO clinical trials are designed to evaluate the safety and efficacy of these drugs in treating various types of cancer. IO clinical trials are conducted in phases, with each phase designed to assess different aspects of the drug's safety and efficacy. Phase I trials are typically conducted in small groups of patients to assess the drug's safety and tolerability. Phase II trials are larger and are designed to assess the drug's efficacy in treating a specific type of cancer. Phase III trials are the largest and are designed to compare the drug's efficacy to existing treatments. Some of the major companies in the IO clinical trials market include Merck, Bristol-Myers Squibb, AstraZeneca, Roche, and Novartis. These companies are actively involved in the development and testing of IO drugs for the treatment of various types of cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.